In this context, in a subset of 52 high-risk locally advanced STS tumor patients derived from a large international study with 328 participants [22] 54% and 15% were positive for P-gp and MRP-1 expression, respectively, with high incidence of P-gp in synovial sarcoma (73%). This evidence concerns the gene PGP and synovial sarcoma.